Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
Genmab is going after a T-cell engager (TCE) for the treatment of non-small cell lung cancer (NSCLC), with PIII development now in the works globally including Japan. The drug, acasunlimab, targets PD-L1 on cancer cells and the costimulatory molecule 4-1BB…
To read the full story
Related Article
- Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
July 18, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
July 3, 2025
- Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
- Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
May 27, 2025
BUSINESS
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Retevmo Now Available in Tablet Form: Lilly Japan
December 8, 2025
- Japan Ethical Drug Sales Rise 5.9% in October: Crecon
December 8, 2025
- Takeda Closes Innovent Oncology Deal, Bags Rights to 2 Late-Stage Assets
December 8, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…